進行性または転移性乳がん患者にPF-07220060を投与した場合のベプデゲストラントについて学ぶ研究。
介入安全性および有効性フェーズ1B/2、PF-07220060と組み合わせた経口タンパク質分解を標的としたキメラであるベプデゲストラント(ARV-471/PF-07850327)の忍容性、PK、および抗腫瘍活性を調査する非盲検試験参加者の高齢者ER+/HER2-の進行性または転移性乳がんを患う18歳以上
The purpose of this study is to learn about the safety and effects of giving vepdegestrant along with PF-07220060. Vepdegestrant is studied to see if it can be a possible treatment for advanced metastatic breast cancer. This type of cancer would have spread from where it started (breast) to other parts of the body and would be tough to treat. The study is seeking for participants who have breast cancer that:
- is hard to treat (advanced) and may have spread to other organs (metastatic).
- is sensitive to hormonal therapy (it is called estrogen receptor positive).
- is no longer responding to treatments taken before starting this study.
All the participants will receive vepdegestrant and PF-07220060. Both medicines will be taken by mouth. The medicines will be taken at home. The experience of people receiving the study medicines will be studied. This will help see if the study medicines are safe and effective. Participants will continue to take vepdegestrant and PF-07220060 until:
- their cancer is no longer responding, or
- side effects become too severe. They will have visits at the study clinic about every 4 weeks.
調査の概要
詳細な説明
C4891026 is a prospective, open-label, multicenter, Phase 1b/2 study to evaluate the safety, antitumor activity, and pharmacokinetic (PK) of vepdegestrant in combination with PF-07220060 in the treatment of participants with Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Advanced or Metastatic Breast Cancer.
研究の種類
入学 (実際)
段階
- フェーズ2
- フェーズ 1
連絡先と場所
研究場所
-
-
Arkansas
-
Fayetteville、Arkansas、アメリカ、72703
- Highlands Oncology
-
Rogers、Arkansas、アメリカ、72758
- Highlands Oncology
-
Springdale、Arkansas、アメリカ、72762
- Highlands Oncology Group
-
-
California
-
Irvine、California、アメリカ、92618
- Hoag Hospital Irvine
-
Irvine、California、アメリカ、92618
- Hoag Health Center Irvine
-
Newport Beach、California、アメリカ、92663
- Hoag Memorial Hospital Presbyterian
-
Palo Alto、California、アメリカ、94304
- Stanford Cancer Center
-
Palo Alto、California、アメリカ、94304
- Clinical and Translational Research Unit (CTRU)
-
Palo Alto、California、アメリカ、94304
- Stanford Cancer Institute - Clinical Trials Office
-
San Francisco、California、アメリカ、94158
- UCSF Medical Center at Mission Bay
-
-
Colorado
-
Fort Collins、Colorado、アメリカ、80524
- UCHealth Poudre Valley Hospital
-
Fort Collins、Colorado、アメリカ、80528
- UCHealth Harmony
-
Greeley、Colorado、アメリカ、80634
- UCHealth Greeley Hospital
-
Loveland、Colorado、アメリカ、80538
- UCHealth - Medical Center of the Rockies
-
-
Connecticut
-
New Haven、Connecticut、アメリカ、06511
- Smilow Cancer Hospital Phase 1 Unit
-
New Haven、Connecticut、アメリカ、06510
- Smilow Cancer Hospital - Yale New Haven Health
-
New Haven、Connecticut、アメリカ、06510
- Yale - New Haven Hospital - Yale Cancer Center
-
Trumbull、Connecticut、アメリカ、06611
- Smilow Cancer Hospital - Trumbull
-
-
Michigan
-
Grand Rapids、Michigan、アメリカ、49546
- START Midwest
-
-
New Jersey
-
Basking Ridge、New Jersey、アメリカ、07920
- MSK Basking Ridge
-
Middletown、New Jersey、アメリカ、07748
- MSK Monmouth
-
Montvale、New Jersey、アメリカ、07645
- MSK Bergen
-
-
New York
-
Commack、New York、アメリカ、11725
- MSK Commack
-
Harrison、New York、アメリカ、10604
- MSK Westchester
-
New York、New York、アメリカ、10065
- Memorial Sloan Kettering Cancer Center
-
New York、New York、アメリカ、10022
- Rockefeller Outpatient Pavilion (53rd Street)
-
New York、New York、アメリカ、10065
- Evelyn H. Lauder Breast and Imaging Center (BAIC).
-
Uniondale、New York、アメリカ、11553
- MSK Nassau
-
-
Texas
-
San Antonio、Texas、アメリカ、78229
- START San Antonio
-
-
Utah
-
Farmington、Utah、アメリカ、84025
- University of Utah, Farmington Health Center
-
Salt Lake City、Utah、アメリカ、84112
- Huntsman Cancer Institute
-
Salt Lake City、Utah、アメリカ、84106
- University of Utah, Sugar House Health Center
-
South Jordan、Utah、アメリカ、84106
- South Jordan Health Center - University of Utah
-
West Valley City、Utah、アメリカ、84119
- START Mountain Region
-
-
-
-
Ontario
-
Ottawa、Ontario、カナダ、K1H 8L6
- The Ottawa Hospital - General Campus
-
Toronto、Ontario、カナダ、M5G 2M9
- Princess Margaret Cancer Centre
-
Toronto、Ontario、カナダ、M4N 3M5
- Sunnybrook Research Institute
-
-
-
-
-
Seville、スペイン、41013
- Hospital Universitario Virgen Del Rocio
-
-
Barcelona [barcelona]
-
Barcelona、Barcelona [barcelona]、スペイン、08035
- Hospital Universitari Vall d'Hebron
-
-
Lleida [lérida]
-
Lleida、Lleida [lérida]、スペイン、25198
- Hospital Universitario Arnau de Vilanova de Lleida
-
-
Madrid, Comunidad de
-
Madrid、Madrid, Comunidad de、スペイン、28041
- Hospital Universitario 12 de Octubre
-
-
-
-
Hérault
-
Montpellier、Hérault、フランス、34298
- Institut Régional du Cancer Montpellier
-
-
Loire-atlantique
-
Saint-Herblain、Loire-atlantique、フランス、44805
- Institut de Cancérologie de l'Ouest
-
-
Provence-Alpes-Côte d'Azur Region
-
Marseille、Provence-Alpes-Côte d'Azur Region、フランス、13273
- Institut Paoli-Calmettes
-
-
-
-
-
Mayagüez、プエルトリコ、00680
- BRCR Global - Mayaguez Administrative Office
-
Mayagüez、プエルトリコ、00682
- BRCR Global - Mayagüez
-
Rio Piedras、プエルトリコ、00935
- Pan American Center for Oncology Trials, LLC
-
-
-
-
Antwerpen
-
Edegem、Antwerpen、ベルギー、2650
- Antwerp University Hospital
-
-
Bruxelles-capitale, Région de
-
Anderlecht、Bruxelles-capitale, Région de、ベルギー、1070
- Institut Jules Bordet
-
-
Vlaams-brabant
-
Leuven、Vlaams-brabant、ベルギー、3000
- UZ Leuven
-
-
West-vlaanderen
-
Kortrijk、West-vlaanderen、ベルギー、8500
- AZ Groeninge Campus Kennedylaan
-
-
-
-
Guangdong
-
Guangzhou、Guangdong、中国、510060
- Sun Yat-sen University Cancer Center
-
-
Hubei
-
Wuhan、Hubei、中国、430023
- Wuhan Union Hospital Cancer Center
-
-
Shaanxi
-
Xi'an、Shaanxi、中国、710061
- The First Affiliated Hospital of Xi'an Jiaotong University
-
-
-
-
-
Tokyo、日本、142-8666
- Showa Medical University Hospital
-
-
Chiba
-
Kashiwa、Chiba、日本、277-8577
- National Cancer Center Hospital East
-
-
Kanagawa
-
Yokohama、Kanagawa、日本、2418515
- Kanagawa cancer center
-
-
Tokyo
-
Chuo-ku、Tokyo、日本、104-0045
- National Cancer Center Hospital
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
-
Histological or cytological diagnosis of breast cancer. At time of enrollment this must not be amenable to surgical resection with curative intent (≥1% ER+ stained cells as per local practice on the most recent tumor biopsy HER2- tumor by IHC or in-situ hybridization per ASCO/CAP).
-
prior anticancer therapies: Phase 1b: at least 1 line of SOC for A/MBC; Prior fulvestrant allowed; ≤1 prior chemotherapy line (no antibody-drug conjugates permitted) for A/MBC setting allowed. Phase 2: At least one and maximum 2 lines of ET in A/MBC setting and most recent ET-based regimen for >6 months.
1, and only 1, prior CDK4/6 inhibitor-based regimen required. Up to 1 prior regimen of cytotoxic chemotherapy (no antibody-drug conjugates permitted) in the A/MBC setting; Prior fulvestrant allowed.
-
Participant with only non-measurable lesion (Phase1b) or at least 1 measurable lesion as defined by RECIST v1.1. (Phase2) are eligible.
-
ECOG PS = 0 or 1 (Phase1b) ; ≤2 (Phase2)
Exclusion Criteria:
- visceral crisis at risk of life-threatening complications in the short term.
- Any condition precluding an adeguate absorption of study interventions.
- newly diagnosed brain metastases, or symptomatic central nervous system (CNS) metastases, carcinomatous meningitis, or leptomeningeal disease. Participants with a history of CNS metastases or cord compression are eligible if they have been definitively treated, clinically stable and discontinued anti-seizure medications and corticosteroids for at least 28 days prior to enrollment in the of study.
- history of any other tumor malignancies within the past 3 years, except for the following: (1) adequately treated basal or squamous cell carcinoma of the skin; (2) curatively treated in situ carcinoma of the cervix. Inflammatory breast cancer are excluded
- impaired cardiovascular function or clinically significant cardiovascular diseases.
- concurrent administration of medications, food, or herb supplements that are strong inhibitors/inducers of CYP3A or UGT2B7, moderate inducers of CYP34 (Phase1b only) and drugs known to predispose to Torsade de Pointes or QT interval prolongation.
- renal impairment, not adequate liver function and/or bone marrow function.
- known active infection
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:なし
- 介入モデル:順次割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:vepdegestrant in combination with PF-07220060
vepdegestrant administered orally once daily (QD) continuously and PF-07220060 administered orally twice daily (BID) continuously on 28-day cycles |
Daily oral dosages of vepdegestrant continuously, dose escalation/de-escalation in Phase 1b until recommended phase 2 dose (RP2D) determined, cycles lasting 28 days
他の名前:
Daily oral dosages of PF-07220060 continuously, dose escalation/de-escalation in Phase 1b until recommended phase 2 dose (RP2D) determined, cycles lasting 28 days |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Number of Participants With Dose-Limiting Toxicities (DLTs): Phase 1b
時間枠:Cycle 1 (28 days)
|
Hematological DLT: neutropenic fever; Grade>=3 thrombocytopenia associated with Grade>=2(clinically significant)bleeding and Grade4 neutropenia/thrombocytopenia lasting <7 days. Non-hematological: Grade>=3 toxicities clinically significant,except those that were not been maximally treated;Grade 2 aspartate aminotransferase(AST), alanine aminotransferase(ALT)/alkaline phosphatase(ALP) levels at baseline as result of liver/bone metastasis,AST,ALT and ALP level>8*baseline/AST/ALT >5*baseline for>=14 days; Hy's Law(concomitant ALT/AST elevation of >=3*upper limit of normal [ULN], total bilirubin elevation>=2*ULN without clear alternative etiology); Grade≥3 electrolyte abnormality with clinical sequelae; QTcF prolongation:any Grade>=3 QT prolongation without clear alternative etiology;any adverse event (AE) attributed to Vepdegestrant and/or PF-07220060 resulting in failure to deliver 75% of doses for either/both agents and any death not clearly due to underlying disease/extraneous causes. |
Cycle 1 (28 days)
|
|
Percentage of Participants With Confirmed Objective Response (OR) by Derived Investigator Assessment: Phase 2
時間枠:From the date of first dose of study treatment combination until the first documentation of disease progression (PD), death or start of new anticancer therapy, whichever occurred first (maximum treatment exposure of 9.5 months for Phase 2)
|
OR was defined as best overall response (BOR) of confirmed complete response (CR) or partial response (PR) according to response evaluation criteria in solid tumors (RECIST) version (v) 1.1. CR was defined as complete disappearance of all target lesions, except for nodal disease, complete disappearance of all non-target lesions and no new lesions. All nodes, both target and non-target, must decrease to normal (short axis <10 millimeter [mm]). PR was defined as at least a >=30% decrease from baseline in the sum of diameters of all target lesions. The short diameter was used in the sum for nodal target lesions, while the longest diameter was used in the sum for non-nodal target lesions, all target lesions were assessed. |
From the date of first dose of study treatment combination until the first documentation of disease progression (PD), death or start of new anticancer therapy, whichever occurred first (maximum treatment exposure of 9.5 months for Phase 2)
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Number of Participants With Treatment Emergent Adverse Events (TEAEs), Treatment Emergent Serious Adverse Events (TESAEs) and Treatment Related TEAEs: Phase 1b
時間枠:From the date of first dose of study treatment combination through study completion
|
AE: any untoward medical occurrence in clinical study participant, temporally associated with use of study treatment, whether or not considered related to study treatment. Serious adverse event (SAE): any untoward medical occurrence, at any dose met one or more of following criteria: death, life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect or other important medical events. AEs includes both SAEs and all other AEs (non-SAEs). TEAEs will be those events with onset dates occurring during the on-treatment period. Relatedness to study drug judged by investigator. |
From the date of first dose of study treatment combination through study completion
|
|
Number of Participants With Laboratory Abnormalities: Phase 1b
時間枠:From the date of first dose of study treatment combination through study completion
|
Laboratory parameters assessed: hemoglobin, platelets, white blood cells (WBC), absolute neutrophils, absolute lymphocytes, absolute monocytes, absolute eosinophils, absolute basophils, alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), sodium, potassium, magnesium, chloride, total calcium, total bilirubin, urea or blood urea nitrogen (BUN), creatinine, estimated glomerular filtration rate (eGFR), uric acid, glucose (fasted), albumin, phosphorus, lipase and amylase. |
From the date of first dose of study treatment combination through study completion
|
|
Number of Participants With Electrocardiogram (ECG) Abnormalities: Phase 1b
時間枠:From the date of first dose of study treatment combination through study completion
|
Twelve lead ECGs were measured with the participant in a supine position after at least 5 minutes. |
From the date of first dose of study treatment combination through study completion
|
|
Percentage of Participants With Confirmed OR by Derived Investigator Assessment: Phase 1b
時間枠:From the date of first dose of study treatment combination through study completion
|
OR was defined as BOR of confirmed CR or PR according to RECIST v 1.1. CR was defined as complete disappearance of all target lesions, except for nodal disease, complete disappearance of all non-target lesions and no new lesions. All nodes, both target and non-target, must decrease to normal (short axis <10 mm). PR was defined as at least a >=30% decrease from baseline in the sum of diameters of all target lesions. The short diameter was used in the sum for nodal target lesions, while the longest diameter was used in the sum for non-nodal target lesions, all target lesions were assessed. |
From the date of first dose of study treatment combination through study completion
|
|
Duration of Response (DOR) by Derived Investigator Assessment: Phase 1b
時間枠:From the date of first dose of study treatment combination through study completion
|
DoR: for participants with OR: time from first documentation of CR/PR to first documentation of PD/death. CR: complete disappearance of all target lesions (L), except nodal disease, complete disappearance of all non-target L and no new L. Both target and non-target nodes, must decrease to normal. PR: >=30% decrease from baseline in sum of diameters of target L. Short diameter used in sum for nodal target L, longest diameter used in sum for non-nodal target L. PD: 20% increase in sum of diameter of target measurable L above smallest sum observed, minimum absolute increase of 5 mm for target L/unequivocal progression of pre-existing L for non-target L. DOR censored on date of last adequate disease assessment for participants who did not have DOR event, discontinued study treatment due to withdrawal of consent prior to event, started new anticancer therapy prior to event, had event after gap of >2 missing disease assessments, or lost to follow-up. Kaplan-Meier method will be used. |
From the date of first dose of study treatment combination through study completion
|
|
Clinical Benefit Response (CBR) by Derived Investigator Assessment: Phase 1b
時間枠:From the date of first dose of study treatment combination through study completion
|
CBR was defined as percentage of participants with BOR of confirmed CR or PR at any time, or stable disease (SD) >=24 weeks as per RECIST v1.1. CR: complete disappearance of all target lesions, except for nodal disease, complete disappearance of all non-target lesions and no new lesions. All nodes, both target and non-target, must decrease to normal (short axis<10 mm). PR: at least >=30% decrease from baseline in sum of diameters of all target lesions. Short diameter was used in sum for nodal target lesions, while longest diameter was used in sum for non-nodal target lesions, all target lesions were assessed. SD: did not qualify for CR, PR, PD. All target lesions were assessed. PD: 20% increase in sum of diameters of target measurable lesions above smallest sum observed, minimum absolute increase of 5mm for target lesions/unequivocal progression of pre-existing lesions for non-target lesion. |
From the date of first dose of study treatment combination through study completion
|
|
Progression Free Survival (PFS) by Derived Investigator Assessment: Phase 1b
時間枠:From the date of first dose of study treatment combination through study completion
|
PFS was defined as the time from the date of first dose of study interventions to the date of first documentation of PD or death due to any cause, whichever occurred first as per RECIST v1.1. PD: 20% increase in sum of diameters of target measurable lesions above smallest sum observed, minimum absolute increase of 5mm for target lesions/unequivocal progression of pre-existing lesions for non-target lesion. PFS was censored on the date of last adequate disease assessment for those who did not have a PFS event, discontinued the study treatment due to withdrawal of consent prior to an event, started a new anticancer therapy prior to an event, had an event after a gap of 2 or more missing disease assessments, or lost to follow-up. Kaplan-Meier method will be used. |
From the date of first dose of study treatment combination through study completion
|
|
Plasma Concentration of Vepdegestrant (ARV-471) and Its Epimer ARV-473: Phase 1b
時間枠:Cycle 1, Day 8: Pre-dose; Cycle 1 Day 15: Pre-dose, 30 minutes, 1, 2, 4 ,6, 8 and 12 hours post-dose; Cycle 2 Days 1 and 15: Pre-dose, anytime between 4 to 8 hour post-dose; Cycles 3, 5, and 7, Day 1: Pre-dose
|
Plasma concentrations of ARV-471 and its epimer ARV-473 were reported in this outcome measure. |
Cycle 1, Day 8: Pre-dose; Cycle 1 Day 15: Pre-dose, 30 minutes, 1, 2, 4 ,6, 8 and 12 hours post-dose; Cycle 2 Days 1 and 15: Pre-dose, anytime between 4 to 8 hour post-dose; Cycles 3, 5, and 7, Day 1: Pre-dose
|
|
Plasma Concentration of PF-07220060: Phase 1b
時間枠:Pre-dose (0 hour) of Day 8 of Cycle 1; pre-dose (0 hour), 0.5,1,2,4,6,8 and 12 hours post-dose of Day 15 of Cycle 1; Pre-dose (0 hour) and anytime between 4 to 8 hour post-dose of Day 1 and 15 of Cycle 2; Pre-dose (0 hour) of Day 1 of Cycle 3, 5 and 7
|
Pre-dose (0 hour) of Day 8 of Cycle 1; pre-dose (0 hour), 0.5,1,2,4,6,8 and 12 hours post-dose of Day 15 of Cycle 1; Pre-dose (0 hour) and anytime between 4 to 8 hour post-dose of Day 1 and 15 of Cycle 2; Pre-dose (0 hour) of Day 1 of Cycle 3, 5 and 7
|
|
|
Steady State Maximum Observed Plasma Concentration (Cmax,ss) of Vepdegestrant (ARV-471) and Its Epimer ARV-473: Phase 1b
時間枠:Predose (0 hours), 0.5, 1, 2, 4, 6, 8, and 12 hours post dose on Cycle 1 Day 15
|
Cmax,ss was the steady-state maximum concentration of ARV-471 after multiple doses and was directly observed from data. ARV-473 is an epimer of ARV-471. |
Predose (0 hours), 0.5, 1, 2, 4, 6, 8, and 12 hours post dose on Cycle 1 Day 15
|
|
Cmax,ss of PF-07220060: Phase 1b
時間枠:Predose (0 hours), 0.5, 1, 2, 4, 6, 8, and 12 hours post dose on Cycle 1 Day 15
|
Predose (0 hours), 0.5, 1, 2, 4, 6, 8, and 12 hours post dose on Cycle 1 Day 15
|
|
|
Steady State Time to Maximum Plasma Concentration (Tmax,ss) of Vepdegestrant (ARV-471) and Its Epimer ARV-473: Phase 1b
時間枠:Predose (0 hours), 0.5, 1, 2, 4, 6, 8, and 12 hours post dose on Cycle 1 Day 15
|
Tmax,ss was the steady-state time to maximum plasma concentration after multiple doses and was directly observed from data. ARV-473 is an epimer of ARV-471. ARV-473 is an epimer of ARV-471. |
Predose (0 hours), 0.5, 1, 2, 4, 6, 8, and 12 hours post dose on Cycle 1 Day 15
|
|
Tmax,ss of PF-07220060: Phase 1b
時間枠:Predose (0 hours), 0.5, 1, 2, 4, 6, 8, and 12 hours post dose on Cycle 1 Day 15
|
Tmax,ss was the steady-state time to maximum plasma concentration after multiple doses and was directly observed from data. |
Predose (0 hours), 0.5, 1, 2, 4, 6, 8, and 12 hours post dose on Cycle 1 Day 15
|
|
Steady State Area Under the Plasma Concentration-Time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUClast,ss) of Vepdegestrant (ARV-471) and Its Epimer ARV-473: Phase 1b
時間枠:Predose (0 hours), 0.5, 1, 2, 4, 6, 8, and 12 hours post dose on Cycle 1 Day 15
|
AUClast,ss was defined as area under the plasma concentration time curve from time zero to the last measurable concentration as steady state. AUClast,ss was calculated using linear/log trapezoidal method. |
Predose (0 hours), 0.5, 1, 2, 4, 6, 8, and 12 hours post dose on Cycle 1 Day 15
|
|
AUClast,ss of PF-07220060: Phase 1b
時間枠:Predose (0 hours), 0.5, 1, 2, 4, 6, 8, and 12 hours post dose on Cycle 1 Day 15
|
AUClast,ss was defined as area under the plasma concentration time curve from time zero to the last measurable concentration as steady state. AUClast,ss was calculated using linear/log trapezoidal method. |
Predose (0 hours), 0.5, 1, 2, 4, 6, 8, and 12 hours post dose on Cycle 1 Day 15
|
|
Apparent Total Clearance (CL/F) of Vepdegestrant (ARV-471): Phase 1b
時間枠:Predose (0 hours), 0.5, 1, 2, 4, 6, 8, and 12 hours post dose on Cycle 1 Day 15
|
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. CL/F was calculated as dose administered divided by AUCinf. AUCinf was calculated as AUClast + (Clast/kel), where, AUClast= area under the concentration-time curve from time 0 to time of last measurable concentration, Clast was the predicted plasma concentration at the last quantifiable time point estimated from the log-linear regression analysis and kel was the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve. |
Predose (0 hours), 0.5, 1, 2, 4, 6, 8, and 12 hours post dose on Cycle 1 Day 15
|
|
CL/F of PF-07220060: Phase 1b
時間枠:Predose (0 hours), 0.5, 1, 2, 4, 6, 8, and 12 hours post dose on Cycle 1 Day 15
|
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. CL/F was calculated as dose administered divided by AUCinf. AUCinf was calculated as AUClast + (Clast/kel), where, AUClast= area under the concentration-time curve from time 0 to time of last measurable concentration, Clast was the predicted plasma concentration at the last quantifiable time point estimated from the log-linear regression analysis and kel was the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve. |
Predose (0 hours), 0.5, 1, 2, 4, 6, 8, and 12 hours post dose on Cycle 1 Day 15
|
|
Apparent Volume of Distribution (Vz/F) of PF-07220060: Phase 1b
時間枠:Predose (0 hours), 0.5, 1, 2, 4, 6, 8, and 12 hours post dose on Cycle 1 Day 15
|
Vz/F was calculated as Dose/(AUCinf * kel). AUCinf was calculated as AUClast + (Clast/kel), where, AUClast= area under the concentration-time curve from time 0 to time of last measurable concentration, Clast was the predicted plasma concentration at the last quantifiable time point estimated from the log-linear regression analysis and kel was the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve. |
Predose (0 hours), 0.5, 1, 2, 4, 6, 8, and 12 hours post dose on Cycle 1 Day 15
|
|
Terminal Half-Life (t1/2) of PF-07220060: Phase 1b
時間枠:Predose (0 hours), 0.5, 1, 2, 4, 6, 8, and 12 hours post dose on Cycle 1 Day 15
|
T1/2 was calculated as loge(2)/kel, where kel is the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve. |
Predose (0 hours), 0.5, 1, 2, 4, 6, 8, and 12 hours post dose on Cycle 1 Day 15
|
|
DOR by Derived Investigator Assessment: Phase 2
時間枠:From the date of first dose of study treatment combination through study completion
|
DOR: for participants with OR: time from first documentation of CR/PR to first documentation of PD/death. CR: complete disappearance of all target lesions (L), except nodal disease, complete disappearance of all non-target L and no new L. Both target and non-target nodes, must decrease to normal. PR: >=30% decrease from baseline in sum of diameters of target L. Short diameter used in sum for nodal target L, longest diameter used in sum for non-nodal target L. PD: 20% increase in sum of diameter of target measurable L above smallest sum observed, minimum absolute increase of 5 mm for target L/unequivocal progression of pre-existing L for non-target L. DOR censored on date of last adequate disease assessment for participants who did not have DOR event, discontinued study treatment due to withdrawal of consent prior to event, started new anticancer therapy prior to event, had event after gap of >2 missing disease assessments, or lost to follow-up. Kaplan-Meier method will be used. |
From the date of first dose of study treatment combination through study completion
|
|
Percentage of Participants With CBR by Derived Investigator Assessment: Phase 2
時間枠:From the date of first dose of study treatment combination through study completion
|
CBR was defined as percentage of participants with BOR of confirmed CR or PR at any time, or stable disease (SD) >=24 weeks as per RECIST v1.1. CR: complete disappearance of all target lesions, except for nodal disease, complete disappearance of all non-target lesions and no new lesions. All nodes, both target and non-target, must decrease to normal (short axis<10 mm). PR: at least >=30% decrease from baseline in sum of diameters of all target lesions. Short diameter was used in sum for nodal target lesions, while longest diameter was used in sum for non-nodal target lesions, all target lesions were assessed. SD: did not qualify for CR, PR, PD. All target lesions were assessed. PD: 20% increase in sum of diameters of target measurable lesions above smallest sum observed, minimum absolute increase of 5mm for target lesions/unequivocal progression of pre-existing lesions for non-target lesion. |
From the date of first dose of study treatment combination through study completion
|
|
PFS by Derived Investigator Assessment: Phase 2
時間枠:From the date of first dose of study treatment combination through study completion
|
PFS was defined as the time from the date of first dose of study interventions to the date of first documentation of PD or death due to any cause, whichever occurred first as per RECIST v1.1. PD: 20% increase in sum of diameters of target measurable lesions above smallest sum observed, minimum absolute increase of 5mm for target lesions/unequivocal progression of pre-existing lesions for non-target lesion. PFS was censored on the date of last adequate disease assessment for those who did not have a PFS event, discontinued the study treatment due to withdrawal of consent prior to an event, started a new anticancer therapy prior to an event, had an event after a gap of 2 or more missing disease assessments, or lost to follow-up. Kaplan-Meier method will be used. |
From the date of first dose of study treatment combination through study completion
|
|
Overall Survival (OS): Phase 2
時間枠:From the date of first dose of study treatment combination through study completion
|
OS was defined as the time from the date of first dose of study treatment combination to the date of death due to any cause. Participants last known to be alive were censored at the date of last contact. Kaplan-Meier method will be used. |
From the date of first dose of study treatment combination through study completion
|
|
Number of Participants With TEAEs, TESAEs and Treatment Related TEAEs: Phase 2
時間枠:From the date of first dose of study treatment combination through study completion
|
AE: any untoward medical occurrence in clinical study participant, temporally associated with use of study treatment, whether or not considered related to study treatment. SAE: any untoward medical occurrence, at any dose met one or more of following criteria: death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect or other important medical events. AEs includes both SAEs and all other AEs (non-SAEs). TEAEs will be those events with onset dates occurring during the on-treatment period. Relatedness to study drug judged by investigator. |
From the date of first dose of study treatment combination through study completion
|
|
Number of Participants With ECG Abnormalities: Phase 2
時間枠:From the date of first dose of study treatment combination through study completion
|
Twelve lead ECGs were measured with the participant in a supine position after at least 5 minutes. |
From the date of first dose of study treatment combination through study completion
|
|
Number of Participants With Laboratory Abnormalities: Phase 2
時間枠:From the date of first dose of study treatment combination through study completion
|
Laboratory parameters assessed included hemoglobin, platelets, WBC, absolute neutrophils, absolute lymphocytes, absolute monocytes, absolute eosinophils, absolute basophils, ALT, AST, ALP, sodium, potassium, magnesium, chloride, total calcium, total bilirubin, urea or BUN, creatinine, eGFR, uric acid, glucose (fasted), albumin, phosphorus, lipase and amylase. |
From the date of first dose of study treatment combination through study completion
|
|
Plasma Concentration of Vepdegestrant (ARV-471) and Its Epimer ARV-473: Phase 2
時間枠:Cycle 1, Day 15 and Cycle 2 Days 1 and 15: Pre-dose, anytime between 4 to 8 hour post-dose; Cycles 3, 5, and 7, Day 1: Pre-dose
|
Plasma concentrations of ARV-471 and its epimer ARV-473 were reported in this outcome measure. |
Cycle 1, Day 15 and Cycle 2 Days 1 and 15: Pre-dose, anytime between 4 to 8 hour post-dose; Cycles 3, 5, and 7, Day 1: Pre-dose
|
|
Plasma Concentration of PF-07220060: Phase 2
時間枠:Cycle 1, Day 15 and Cycle 2 Days 1 and 15: Pre-dose, anytime between 4 to 8 hours post-dose; Cycles 3, 5, and 7, Day 1: Pre-dose
|
Plasma concentrations of ARV-471 and its epimer ARV-473 were reported in this outcome measure. |
Cycle 1, Day 15 and Cycle 2 Days 1 and 15: Pre-dose, anytime between 4 to 8 hours post-dose; Cycles 3, 5, and 7, Day 1: Pre-dose
|
|
Change From Baseline in Circulating Tumor Deoxyribonucleic Acid (ctDNA) Plasma Level: Phase 2
時間枠:Baseline and up to End of Treatment
|
Baseline and up to End of Treatment
|
協力者と研究者
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
- C4891026
- 2023-508130-33-00 (レジストリ識別子:CTIS (EU))
- TACTIVE-K (その他の識別子:Alias Study Number)
- 2023 (米国 NIH グラント/契約)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。